» Articles » PMID: 35596914

Psychosocial Risk Factors for Alzheimer's Disease in Patients with Down Syndrome and Their Association with Brain Changes: A Narrative Review

Overview
Journal Neurol Ther
Publisher Springer
Specialty Neurology
Date 2022 May 21
PMID 35596914
Authors
Affiliations
Soon will be listed here.
Abstract

Several recent epidemiological studies attempted to identify risk factors for Alzheimer's disease. Age, family history, genetic factors (APOE genotype, trisomy 21), physical activity, and a low level of schooling are significant risk factors. In this review, we summarize the known psychosocial risk factors for the development of Alzheimer's disease in patients with Down syndrome and their association with neuroanatomical changes in the brains of people with Down syndrome. We completed a comprehensive review of the literature on PubMed, Google Scholar, and Web of Science about psychosocial risk factors for Alzheimer's disease, for Alzheimer's disease in Down syndrome, and Alzheimer's disease in Down syndrome and their association with neuroanatomical changes in the brains of people with Down syndrome. Alzheimer's disease causes early pathological changes in individuals with Down syndrome, especially in the hippocampus and corpus callosum. People with Down syndrome living with dementia showed reduced volumes of brain areas affected by Alzheimer's disease as the hippocampus and corpus callosum in association with cognitive decline. These changes occur with increasing age, and the presence or absence of psychosocial risk factors impacts the degree of cognitive function. Correlating Alzheimer's disease biomarkers in Down syndrome and cognitive function scores while considering the effect of psychosocial risk factors helps us identify the mechanisms leading to Alzheimer's disease at an early age. Also, this approach enables us to create more sensitive and relevant clinical, memory, and reasoning assessments for people with Down syndrome.

Citing Articles

Distinct neuroanatomical and neuropsychological features of Down syndrome compared to related neurodevelopmental disorders: a systematic review.

Hamadelseed O, Chan M, Wong M, Skutella T Front Neurosci. 2023; 17:1225228.

PMID: 37600012 PMC: 10436105. DOI: 10.3389/fnins.2023.1225228.


Correlating MRI-based brain volumetry and cognitive assessment in people with Down syndrome.

Hamadelseed O, Skutella T Brain Behav. 2023; 13(10):e3186.

PMID: 37496380 PMC: 10570489. DOI: 10.1002/brb3.3186.


Going beyond established model systems of Alzheimer's disease: companion animals provide novel insights into the neurobiology of aging.

de Sousa A, Rigby Dames B, Graff E, Mohamedelhassan R, Vassilopoulos T, Charvet C Commun Biol. 2023; 6(1):655.

PMID: 37344566 PMC: 10284893. DOI: 10.1038/s42003-023-05034-3.


Quality of life in adults with Down syndrome: A mixed methods systematic review.

Ijezie O, Healy J, Davies P, Balaguer-Ballester E, Heaslip V PLoS One. 2023; 18(5):e0280014.

PMID: 37126503 PMC: 10150991. DOI: 10.1371/journal.pone.0280014.

References
1.
Pantel J, Schroder J, Essig M, Minakaran R, Schad L, Friedlinger M . Corpus callosum in Alzheimer's disease and vascular dementia--a quantitative magnetic resonance study. J Neural Transm Suppl. 1998; 54:129-36. DOI: 10.1007/978-3-7091-7508-8_12. View

2.
Reeves R, Irving N, Moran T, WOHN A, Kitt C, Sisodia S . A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995; 11(2):177-84. DOI: 10.1038/ng1095-177. View

3.
Mendez M . Early-Onset Alzheimer Disease. Neurol Clin. 2017; 35(2):263-281. PMC: 5407192. DOI: 10.1016/j.ncl.2017.01.005. View

4.
Kang S, Lee Y, Lee J . Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. Yonsei Med J. 2017; 58(3):479-488. PMC: 5368131. DOI: 10.3349/ymj.2017.58.3.479. View

5.
Wang H, Wahlberg M, Karp A, Winblad B, Fratiglioni L . Psychosocial stress at work is associated with increased dementia risk in late life. Alzheimers Dement. 2012; 8(2):114-20. DOI: 10.1016/j.jalz.2011.03.001. View